ArticleThe Lancet. Global health2020
Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study.
Article in The Lancet. Global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 480 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
480 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.Annals of medicine · 2026Pooled it
- Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- Contribution of mammographic imaging after initial ultrasound in women with focal breast complaints-systematic review.European radiology · 2026Pooled it
- Human betaretrovirus (HBRV), homologous to mouse mammary tumor virus (MMTV), and human breast cancer: a significant epidemiological association.Retrovirology · 2026Pooled it
- Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis.Frontiers in oncology · 2026Pooled it
- Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.British journal of cancer · 2025Pooled it
- Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis.Advances in therapy · 2025Pooled it
- Pooled it
- Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.Journal of the National Cancer Institute · 2025Trial
- Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.Breast cancer (Tokyo, Japan) · 2025Trial
- Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- The NorthMom study: population-based follow-up of women in a birth cohort to assess pregnancy exposures and effects on breast cancer risk factors.BMC public health · 2026Observational
- Physician-patient sex dyads and management of dyslipidaemia and hypertension in primary care: findings from two population-based studies.European heart journal. Quality of care & clinical outcomes · 2026Observational
- Robotic nipple-sparing mastectomy in breast cancer: current evidence, technical considerations, and clinical outcomes.Updates in surgery · 2026Review
- Evaluation of the time‑of‑flight-enhanced deep learning image reconstruction method inPhysical and engineering sciences in medicine · 2026Article
- Article
- Controllable Cascade Aggregation Ion Programmed Nanomachines and Simple Isolation Enable Tumor-Derived Small Extracellular Vesicles Detection for Enhanced Breast Cancer Assessment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Breast Cancer Liver Metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.Research square · 2026Article
- A novel pseudo-five-component synthesis, molecular docking analysis, ADMET and drug likeness studies of new 3,4-dihydro-2RSC advances · 2026Article
- Global patterns, temporal trends and socioeconomic inequalities in the burden of breast cancer: a population-based study across 185 countries.Cancer biology & medicine · 2026Article
420 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundBreast cancer has distinct causes, prognoses, and outcomes and effects in patients at premenopausal and postmenopausal ages. We sought to assess the global burden and trends in breast cancer by menopausal status.
methodsWe did a population-based analysis of global breast cancer incidence and mortality among premenopausal and postmenopausal women. Menopausal status was defined using age as a proxy, whereby breast cancer cases or deaths at age 50 years or older were regarded as postmenopausal. Age-standardised breast cancer incidence and mortality in 2018 were calculated using GLOBOCAN data. Incidence trends for 1998-2012 were assessed in 44 populations from 41 countries using the Cancer in Five Continents plus database, by calculating the annual average percent change.
findingsApproximately 645 000 premenopausal and 1·4 million postmenopausal breast cancer cases were diagnosed worldwide in 2018, with more than 130 000 and 490 000 deaths occurring in each menopausal group, respectively. Proportionally, countries with a low UNDP human development index (HDI) faced a greater burden of premenopausal breast cancer for both new cases and deaths compared with higher income countries. Countries with a very high HDI had the highest premenopausal and postmenopausal breast cancer incidence (30·6 and 253·6 cases per 100 000, respectively), whereas countries with low and medium HDI had the highest premenopausal and postmenopausal mortality, respectively (8·5 and 53·3 deaths per 100 000, respectively). When examining breast cancer trends, we noted significantly increasing age-standardised incidence rates (ASIRs) for premenopausal breast cancer in 20 of 44 populations and significantly increasing ASIRs for postmenopausal breast cancer in 24 of 44 populations. The growth exclusively at premenopausal ages largely occurred in high-income countries, whereas the increasing postmenopausal breast cancer burden was most notable in countries under transition.
interpretationWe provide evidence of a rising burden of both premenopausal and postmenopausal breast cancer worldwide. Although early diagnosis and access to treatment remain crucial in low-income and middle-income countries, primary prevention efforts seeking to decrease exposure to known breast cancer risk factors are warranted in all world regions to curb the future breast cancer burden.
fundingNone.
Indexed as
Identifiers
32710860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.